New pill aims to prevent fat spike after Weight-Loss drug stop

NCT ID NCT06640972

Completed Disease control Sponsor: Response Pharmaceuticals Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jul 02, 2026 · Updated 2 times

Summary

This study tested whether the drug RDX-002 can lower high blood fat levels in people who recently stopped taking weight-loss medications like semaglutide or tirzepatide. Sixty-eight adults who had lost at least 10% of their body weight on those drugs took either RDX-002 or a placebo daily for 12 weeks. The main goal was to see if RDX-002 reduces triglycerides after a fatty meal, while also checking effects on weight and cholesterol.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: RDX-002 (a drug that blocks fat absorption in the gut)
What this could lead to: If it works, RDX-002 could help people maintain healthier blood fat levels after stopping popular weight-loss injections.
What could go wrong: This is a small, early-phase trial with only 68 participants. The drug may not work better than placebo, and side effects from blocking fat absorption are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHOLESTEROL, ELEVATED are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Body-Weight Trajectory Hypercholesterolemia hyperlipidemia hypertriglyceridemia Obesity obesity disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CHOLESTEROL, ELEVATED TRIGLYCERIDES WEIGHT GAIN TRAJECTORY

Contacts and locations

Locations

Nucleus Network

Saint Paul, Minnesota, 55114, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.